Locations:
Search IconSearch
May 15, 2018/News Releases

Cleveland Clinic Researcher Receives $2M Grant to Study Role of Cancer’s Genetic Composition in Predicting the Effectiveness of Radiation Therapy

Mohamed Abazeed, M.D., Ph.D., is committed to moving radiotherapy beyond a “one-size-fits-all” approach

Media Contact

Cleveland Clinic News Service | 216.444.0141

We’re available to shoot custom interviews & b-roll for media outlets upon request.

Media Downloads

CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.

images: 0

video: 0

audio: 0

text: 0

gene

Can the genetic makeup of their cancers predict how patients with lung cancer will respond to radiation therapy? And can this information be used to advance a genetically guided strategy for patients with these tumors? Cleveland Clinic researcher and radiation oncologist Mohamed Abazeed, M.D., Ph.D., has been awarded a $2 million grant from the National Cancer Institute (NCI) to delve into those and other related questions.

Dr. Abazeed’s overall objective for this award is to identify new genetic markers calibrated on the basis of radiation therapy effectiveness and new drug-radiation therapy strategies that more precisely and effectively target the most resistant lung tumors to radiation.

“Current radiation therapy regimens use a ‘one-size-fits-all’ approach, not taking into account the genetic content of individual tumors,” said Dr. Abazeed. “There is an urgent need to identify genetic markers that can recognize tumors that are more or less likely to respond to radiotherapy and translate these markers for clinical use. This more personalized approach not only can improve treatment responses, but it can also potentially reduce toxicity, resulting in an improved quality of life for survivors who received these treatments.”

Efforts to predict the response to radiotherapy thus far have been limited in large part because the genetic features that regulate tumor survival – and their frequency across and within individual cancer types – had not been studied on a large-scale. In 2016, Dr. Abazeed’s lab published results of the largest profiling effort of cancer cell survival after radiation, comprising a collection of 533 genetically annotated tumor cell lines from 26 cancer types. Results showed significant biological diversity in the survival of cancer cells after exposure to ionizing radiation, and offered evidence that new genetic features regulating cellular response to these treatments can be identified.

Dr. Abazeed’s new NCI-funded investigation aims to advance the clinical translation of a short list of the most important regulators of radiation resistance in lung cancer. The molecular pathways implicated in their studies are found in as high as approximately 30% of patients or as low as 7%. His preliminary work suggests that specific mutations in these pathways confer a strong phenotype of radiation resistance in cells, human-derived mouse xenografts and patients with non-small-cell lung cancer.

Dr. Abazeed’s profiling efforts have also demonstrated that some mutations that cause resistance to radiation can sometimes represent a minor component of the tumor, or are subclonal. Dr. Abazeed contends that these subclones can become dominant during the course of radiation. This treatment-associated subclonal evolution may have significant implications for the ability of radiation to effect complete tumor eradication. On the basis of these studies, Dr. Abazeed seeks to advance a genetically-guided radiosensitization strategy that makes tumor cells more sensitive to radiation therapy.

“If these hypotheses are correct, our results will demonstrate that radiotherapeutic sensitizers can be selected based on both the identity and type of genetic alterations identified in a patient’s cancer, prompting an evolution in the use of radiation from a generic approach to one that is guided by the genetic composition of individual tumors,” added Dr. Abazeed.

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 81,000 employees worldwide are more than 5,743 salaried physicians and researchers, and 20,160 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,690-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 276 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2023, there were 13.7 million outpatient encounters, 323,000 hospital admissions and observations, and 301,000 surgeries and procedures throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 132 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/CleClinicNews. News and resources available at newsroom.clevelandclinic.org.

Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.

Latest from the Newsroom